The Employers’ Guide to GLP-1s

Breakthrough anti-obesity medications called GLP-1s have revolutionized the treatment landscape for obesity. While these medications have proven effective, they can be costly. If just half of those eligible sought GLP-1s for weight loss, prescription costs could increase by more than $840 per member per year across the entire population. Now more than ever before, employers need a proactive GLP-1 strategy to eliminate unnecessary spend, while optimizing health outcomes.  

In this white paper, you’ll discover:

• The latest evidence behind GLP-1s
• Why GLP-1s may not be for everyone
• The importance of a multidisciplinary, stepped care approach to sustain long-term health outcomes and control costs